View in EDS

HSR26-204: Baseline EORTC QLQ-C30 "Clinically Important" Symptom Burden Predicts Survival and Toxicity in CLL/SLL Across Randomized Ibrutinib Trials.

Saved in:
Bibliographic Details
Title: HSR26-204: Baseline EORTC QLQ-C30 "Clinically Important" Symptom Burden Predicts Survival and Toxicity in CLL/SLL Across Randomized Ibrutinib Trials.
Authors: Abuhelwa AY; 1College of Pharmacy, University of Sharjah, Sharjah, UAE; HOA., Almansour SA; 1College of Pharmacy, University of Sharjah, Sharjah, UAE; HOA., Al-Shamsi HO; 2Burjeel Cancer Institute, Burjeel Medical City, Abu Dhabi, UAE.; 3Harvard Medical School, Harvard University, Boston, MA., Abuhelwa Z; 4University of South Florida/H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL., Ziade MA; 5Department of Hematology, Medcare Royal Specialty Hospital, Dubai, UAE., McKinnon RA; 6College of Medicine and Public Health, Flinders University, Bedford Park, South Australia, Australia., Sorich MJ; 6College of Medicine and Public Health, Flinders University, Bedford Park, South Australia, Australia., Hopkins AM; 6College of Medicine and Public Health, Flinders University, Bedford Park, South Australia, Australia.
Source: Journal of the National Comprehensive Cancer Network : JNCCN [J Natl Compr Canc Netw] 2026 Mar 31; Vol. 24 (3.5). Date of Electronic Publication: 2026 Mar 31.
Publication Type: Journal Article
Journal Info: Publisher: Harborside Press Country of Publication: United States NLM ID: 101162515 Publication Model: Electronic Cited Medium: Internet ISSN: 1540-1413 (Electronic) Linking ISSN: 15401405 NLM ISO Abbreviation: J Natl Compr Canc Netw Subsets: MEDLINE; In Process
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41991051
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: HSR26-204: Baseline EORTC QLQ-C30 "Clinically Important" Symptom Burden Predicts Survival and Toxicity in CLL/SLL Across Randomized Ibrutinib Trials.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Abuhelwa+AY%22">Abuhelwa AY</searchLink>; 1College of Pharmacy, University of Sharjah, Sharjah, UAE; HOA.<br /><searchLink fieldCode="AU" term="%22Almansour+SA%22">Almansour SA</searchLink>; 1College of Pharmacy, University of Sharjah, Sharjah, UAE; HOA.<br /><searchLink fieldCode="AU" term="%22Al-Shamsi+HO%22">Al-Shamsi HO</searchLink>; 2Burjeel Cancer Institute, Burjeel Medical City, Abu Dhabi, UAE.; 3Harvard Medical School, Harvard University, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Abuhelwa+Z%22">Abuhelwa Z</searchLink>; 4University of South Florida/H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.<br /><searchLink fieldCode="AU" term="%22Ziade+MA%22">Ziade MA</searchLink>; 5Department of Hematology, Medcare Royal Specialty Hospital, Dubai, UAE.<br /><searchLink fieldCode="AU" term="%22McKinnon+RA%22">McKinnon RA</searchLink>; 6College of Medicine and Public Health, Flinders University, Bedford Park, South Australia, Australia.<br /><searchLink fieldCode="AU" term="%22Sorich+MJ%22">Sorich MJ</searchLink>; 6College of Medicine and Public Health, Flinders University, Bedford Park, South Australia, Australia.<br /><searchLink fieldCode="AU" term="%22Hopkins+AM%22">Hopkins AM</searchLink>; 6College of Medicine and Public Health, Flinders University, Bedford Park, South Australia, Australia.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101162515%22">Journal of the National Comprehensive Cancer Network : JNCCN</searchLink> [J Natl Compr Canc Netw] 2026 Mar 31; Vol. 24 (3.5). <i>Date of Electronic Publication: </i>2026 Mar 31.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Harborside+Press%22">Harborside Press </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101162515 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1540-1413 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2215401405%22">15401405 </searchLink><i>NLM ISO Abbreviation: </i>J Natl Compr Canc Netw <i>Subsets: </i>MEDLINE; In Process
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41991051
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.6004/jnccn.2025.7459
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: HSR26-204: Baseline EORTC QLQ-C30 "Clinically Important" Symptom Burden Predicts Survival and Toxicity in CLL/SLL Across Randomized Ibrutinib Trials.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Abuhelwa AY
      – PersonEntity:
          Name:
            NameFull: Almansour SA
      – PersonEntity:
          Name:
            NameFull: Al-Shamsi HO
      – PersonEntity:
          Name:
            NameFull: Abuhelwa Z
      – PersonEntity:
          Name:
            NameFull: Ziade MA
      – PersonEntity:
          Name:
            NameFull: McKinnon RA
      – PersonEntity:
          Name:
            NameFull: Sorich MJ
      – PersonEntity:
          Name:
            NameFull: Hopkins AM
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 31
              M: 03
              Text: 2026 Mar 31
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1540-1413
          Numbering:
            – Type: volume
              Value: 24
            – Type: issue
              Value: 3.5
          Titles:
            – TitleFull: Journal of the National Comprehensive Cancer Network : JNCCN
              Type: main
ResultId 1